TYMS and neoplasm: We have recently reported that concurrent targeting of BRCA2 and thymidylate synthase in A549 and Hela cells with antisense molecules sensitizes these human tumor cells to cisplatin and melphalan in a fashion consistent with complementary lethality [26].